169 related articles for article (PubMed ID: 26521960)
1. Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases.
Szelag M; Wesoly J; Bluyssen HA
Curr Protein Pept Sci; 2016; 17(2):135-46. PubMed ID: 26521960
[TBL] [Abstract][Full Text] [Related]
2. Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.
Szeląg M; Czerwoniec A; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2014 Oct; 740():417-20. PubMed ID: 25183399
[TBL] [Abstract][Full Text] [Related]
3. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.
Szelag M; Piaszyk-Borychowska A; Plens-Galaska M; Wesoly J; Bluyssen HA
Oncotarget; 2016 Jul; 7(30):48788-48812. PubMed ID: 27166190
[TBL] [Abstract][Full Text] [Related]
5. Signal transducers and activators of transcription as targets for small organic molecules.
Berg T
Chembiochem; 2008 Sep; 9(13):2039-44. PubMed ID: 18677740
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs.
Plens-Galaska M; Szelag M; Collado A; Marques P; Vallejo S; Ramos-González M; Wesoly J; Sanz MJ; Peiró C; Bluyssen HAR
Front Immunol; 2018; 9():2141. PubMed ID: 30283459
[TBL] [Abstract][Full Text] [Related]
8. Targeting STATs in neuroinflammation: The road less traveled!
Nabavi SM; Ahmed T; Nawaz M; Devi KP; Balan DJ; Pittalà V; Argüelles-Castilla S; Testai L; Khan H; Sureda A; de Oliveira MR; Vacca RA; Xu S; Yousefi B; Curti V; Daglia M; Sobarzo-Sánchez E; Filosa R; Nabavi SF; Majidinia M; Dehpour AR; Shirooie S
Pharmacol Res; 2019 Mar; 141():73-84. PubMed ID: 30550953
[TBL] [Abstract][Full Text] [Related]
9. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Buettner R; Mora LB; Jove R
Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
[TBL] [Abstract][Full Text] [Related]
10. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.
Nikitakis NG; Siavash H; Sauk JJ
Curr Cancer Drug Targets; 2004 Dec; 4(8):637-51. PubMed ID: 15578920
[TBL] [Abstract][Full Text] [Related]
11. STAT 3 as a target for cancer drug discovery.
Costantino L; Barlocco D
Curr Med Chem; 2008; 15(9):834-43. PubMed ID: 18473793
[TBL] [Abstract][Full Text] [Related]
12. The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.
Desrivières S; Kunz C; Barash I; Vafaizadeh V; Borghouts C; Groner B
J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):75-87. PubMed ID: 16947086
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.
Wang W; Lopez McDonald MC; Hariprasad R; Hamilton T; Frank DA
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611065
[TBL] [Abstract][Full Text] [Related]
14. Expression of STATs and their inhibitors SOCS and PIAS in brain tumors. In vitro and in vivo study.
Ehrmann J; Strakova N; Vrzalikova K; Hezova R; Kolar Z
Neoplasma; 2008; 55(6):482-7. PubMed ID: 18999875
[TBL] [Abstract][Full Text] [Related]
15. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
Goropevšek A; Holcar M; Avčin T
Clin Rev Allergy Immunol; 2017 Apr; 52(2):164-181. PubMed ID: 27216430
[TBL] [Abstract][Full Text] [Related]
16. STAT inhibitors for cancer therapy.
Furqan M; Akinleye A; Mukhi N; Mittal V; Chen Y; Liu D
J Hematol Oncol; 2013 Dec; 6():90. PubMed ID: 24308725
[TBL] [Abstract][Full Text] [Related]
17. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells.
Nagel-Wolfrum K; Buerger C; Wittig I; Butz K; Hoppe-Seyler F; Groner B
Mol Cancer Res; 2004 Mar; 2(3):170-82. PubMed ID: 15037656
[TBL] [Abstract][Full Text] [Related]
18. Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives.
Song J; Wang J; Tian S; Li H
Curr Med Chem; 2023; 30(16):1824-1847. PubMed ID: 35986534
[TBL] [Abstract][Full Text] [Related]
19. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.
Groner B; von Manstein V
Mol Cell Endocrinol; 2017 Aug; 451():1-14. PubMed ID: 28576744
[TBL] [Abstract][Full Text] [Related]
20. STAT signaling in the pathogenesis and treatment of cancer.
Frank DA
Mol Med; 1999 Jul; 5(7):432-56. PubMed ID: 10449805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
